CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India - CytoMed Therapeutics (NASDAQ:GDTC), TC BioPharm (Holdings) (OTC:TCBPY)
SINGAPORE, Nov. 18, 2025 ( GLOBE NEWSWIRE ) -- CytoMed Therapeutics Limited ( NASDAQ:GDTC ) ( "CytoMed" or "Company" ) , a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary novel technologies to develop affordable donor-derived cell-based ...
How this was made

The 30-second read
Why it matters
The acquisition is viewed positively by the market, potentially boosting investor confidence and stock valuation.
Market read
The news is relevant primarily to biotech investors and stakeholders interested in immunotherapy advancements.
What to watch
Regulatory hurdles in China and India could delay commercialization and affect stock performance.
Background
CytoMed Therapeutics is expanding its T cell technology platform through strategic acquisitions, aiming to enhance its oncology treatment pipeline.
Ticker impact
High relevance as it is the primary company involved in the news.
Potential upward movement of 5-10% over the next 1-3 weeks.
Strategic acquisitions often lead to positive market perception, but actual price movement depends on broader market conditions.
Market effects
Potential positive sentiment in biotech and immunotherapy sectors.
Limited regional impact, primarily affecting Singapore and UK biotech markets.
Moderate, given the global interest in cancer therapies and biotech acquisitions.
Counterpoint
The acquisition may lead to increased competition or integration challenges, potentially negatively impacting GDTC's stock.
Key entities
- CompanyCytoMed Therapeutics Limited
A Singapore-based biopharmaceutical company focused on cell-based cancer therapies.
- TechnologyT Cell Technology
Innovative immunotherapy platform acquired from UK to treat cancers.




